^
Association details:
| Biomarker: | FASN-L |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | carfilzomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of Carfilzomib (CFZ) in Acute Myeloid Leukemia (AML) As a Single Agent and in Novel Combinations
Published date:
11/04/2020
Excerpt:
RPPA also revealed that lower basal levels of fatty acid synthase (FASN), a key enzyme involved in lipogenesis, correlated with CFZ sensitivity and CFZ resistant lines tendedto have higher basal FASN levels.
